MX366341B - Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. - Google Patents

Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.

Info

Publication number
MX366341B
MX366341B MX2015017609A MX2015017609A MX366341B MX 366341 B MX366341 B MX 366341B MX 2015017609 A MX2015017609 A MX 2015017609A MX 2015017609 A MX2015017609 A MX 2015017609A MX 366341 B MX366341 B MX 366341B
Authority
MX
Mexico
Prior art keywords
peptidomimetics
peptides
treatments
cancer patient
combination uses
Prior art date
Application number
MX2015017609A
Other languages
English (en)
Other versions
MX2015017609A (es
Inventor
Kawabe Takumi
Sato Takuji
Mine Naoki
Saito Naoya
Sakakibara Keiichi
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52141164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366341(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of MX2015017609A publication Critical patent/MX2015017609A/es
Publication of MX366341B publication Critical patent/MX366341B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)

Abstract

La presente invención se refiere a compuestos que incluyen péptidos y peptidomiméticos que se pueden usar para tratar trastornos proliferativos, tales como los asociados con células de tumores benignos y malignos. Mientras la invención no se limita a ningún mecanismo particular, los compuestos de la invención pretenden funcionar al menos parcialmente inhibiendo el punto de control del Ciclo celular G2. Entonces, los compuestos de la invención se pueden usar para inhibir solo el crecimiento celular o se puede usar en combinación con un tratamiento de daño de ácido nucleico para inhibir el crecimiento celular.
MX2015017609A 2013-06-24 2014-06-24 Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer. MX366341B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838777P 2013-06-24 2013-06-24
PCT/IB2014/001579 WO2014207556A1 (en) 2013-06-24 2014-06-24 Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations

Publications (2)

Publication Number Publication Date
MX2015017609A MX2015017609A (es) 2016-04-15
MX366341B true MX366341B (es) 2019-07-05

Family

ID=52141164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015017609A MX366341B (es) 2013-06-24 2014-06-24 Peptidos y peptidomimeticos en usos de combinacion y tratamientos para subpoblaciones de pacientes con cancer.

Country Status (27)

Country Link
US (1) US9221872B2 (es)
EP (1) EP3013351B1 (es)
JP (1) JP6401255B2 (es)
KR (1) KR102247493B1 (es)
CN (1) CN105324121A (es)
AU (1) AU2014300713B2 (es)
BR (1) BR112015032542A2 (es)
CA (1) CA2916136C (es)
CL (1) CL2015003704A1 (es)
CY (1) CY1122523T1 (es)
DK (1) DK3013351T3 (es)
ES (1) ES2765300T3 (es)
HR (1) HRP20192264T1 (es)
HU (1) HUE046873T2 (es)
IL (1) IL243266B (es)
LT (1) LT3013351T (es)
MX (1) MX366341B (es)
MY (1) MY182232A (es)
PH (1) PH12015502855B1 (es)
PL (1) PL3013351T3 (es)
PT (1) PT3013351T (es)
RS (1) RS60180B1 (es)
RU (1) RU2732440C2 (es)
SG (1) SG11201510490VA (es)
SI (1) SI3013351T1 (es)
WO (1) WO2014207556A1 (es)
ZA (1) ZA201600089B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
TWI805542B (zh) * 2015-10-23 2023-06-21 日商坎巴斯有限公司 用於癌症治療之肽及擬肽與t細胞活化劑及/或查核點抑制劑之組合
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
WO2020014646A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン-23受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ.ベー. インターロイキン-23受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
CN116139253B (zh) * 2021-08-10 2025-04-22 昆明医科大学 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863090B1 (ko) * 2002-01-17 2008-10-13 다케다 파머수티컬 컴패니 리미티드 항증식 활성을 지니고/지니거나 핵산 손상제 또는 처리제를 증강시키는 펩티드 및 펩티드모방체
BR0315795A (pt) * 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Pró-medicamentos de monofosfato de citarabina
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
US7479484B2 (en) * 2003-06-25 2009-01-20 Takeda Pharmaceutical Company Limited Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
AR071774A1 (es) * 2008-05-14 2010-07-14 Takeda Pharmaceutical Sal de acetato de un compuesto peptidico que tiene actividad antitumoral y su uso.

Also Published As

Publication number Publication date
SG11201510490VA (en) 2016-01-28
SI3013351T1 (sl) 2020-03-31
NZ715285A (en) 2021-09-24
BR112015032542A2 (pt) 2017-07-25
IL243266A0 (en) 2016-03-31
RU2016101718A3 (es) 2018-03-01
KR102247493B1 (ko) 2021-04-30
WO2014207556A1 (en) 2014-12-31
LT3013351T (lt) 2020-01-10
JP2016522245A (ja) 2016-07-28
HRP20192264T1 (hr) 2020-03-06
PT3013351T (pt) 2020-01-17
ZA201600089B (en) 2020-02-26
PH12015502855A1 (en) 2016-04-04
CL2015003704A1 (es) 2016-07-29
CA2916136C (en) 2022-10-18
AU2014300713B2 (en) 2019-02-14
EP3013351A1 (en) 2016-05-04
IL243266B (en) 2019-11-28
PL3013351T3 (pl) 2020-05-18
US9221872B2 (en) 2015-12-29
RU2016101718A (ru) 2017-07-28
CY1122523T1 (el) 2021-01-27
HK1219905A1 (en) 2017-04-21
KR20160021792A (ko) 2016-02-26
CN105324121A (zh) 2016-02-10
EP3013351B1 (en) 2019-10-30
EP3013351A4 (en) 2017-03-01
RU2732440C2 (ru) 2020-09-16
CA2916136A1 (en) 2014-12-31
HUE046873T2 (hu) 2020-03-30
AU2014300713A1 (en) 2016-01-21
ES2765300T3 (es) 2020-06-08
PH12015502855B1 (en) 2022-02-11
DK3013351T3 (da) 2020-01-27
RS60180B1 (sr) 2020-06-30
MY182232A (en) 2021-01-18
US20150056301A1 (en) 2015-02-26
MX2015017609A (es) 2016-04-15
JP6401255B2 (ja) 2018-10-10

Similar Documents

Publication Publication Date Title
PH12015502855A1 (en) Peptides and petidomimetics in combination uses and treatments for cancer patient subpopulations
ZA201802966B (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
SG10201902380SA (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
PH12014500248B1 (en) Treatment of breast cancer
EP4424326A3 (en) Modified nk-92 cells for treating cancer
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2016004678A (es) Composiciones para el tratamiento del cancer.
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
AU2015279834A8 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
MX377618B (es) Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing.
NZ627480A (en) Inhibitors of iap
SG10201902568YA (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA201492187A1 (ru) Способы лечения солидных опухолей с использованием кофермента q10
PH12015500867A1 (en) Treatment of prostate cancer with tor kinase inhibitors
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
PH12021550035A1 (en) Combination therapy
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
PH12016000355B1 (en) Use of xanthophylls for the treatment of cancers
UA78354U (ru) Способ лечения базально-клеточного рака кожи
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
EA201892813A1 (ru) Иммунотерапия рака
IN2015KN00676A (es)

Legal Events

Date Code Title Description
FG Grant or registration